For more than twenty years, research on psilocybin has focused primarily on mental health. Clinical studies have shown promising results for depression, post-traumatic stress, anxiety, addiction, and emotional distress associated with serious illness. These findings have already changed how many scientists view the therapeutic potential of psychedelic compounds. Today, however, a new question is beginning to emerge.

Could these compounds influence not only the mind, but some of the fundamental biological processes involved in aging itself?

I find this question deeply interesting—not because it promises easy answers, but because it connects several fields that have shaped my work for many years: aging, brain health, dementia, creativity, resilience, and the remarkable capacity of the human organism to adapt.

Looking Beyond Mental Health

Depression, chronic stress, post-traumatic stress disorder (PTSD), and persistent inflammation have all been associated with an increased risk of cognitive decline later in life. They are not direct causes of dementia, but they are increasingly recognized as factors that may influence brain aging and resilience. This is one reason why scientists are paying closer attention to treatments that affect multiple systems simultaneously.

Research on psychedelics is expanding rapidly—from mental health to questions about aging biology. Although these findings are preliminary and not yet demonstrated in humans, they open fascinating scientific questions about neuroplasticity, resilience, and whole-body health.

A Landmark Study on Biological Aging

In 2025, researchers from Emory University and Baylor College of Medicine published a study in npj Aging entitled Psilocybin Treatment Extends Cellular Lifespan and Improves Survival of Aged Mice. It is the first experimental study specifically designed to investigate whether psilocybin might influence recognized biological hallmarks of aging.

The researchers examined both cultured human cells and aged mice.

In laboratory-grown human fibroblasts, exposure to psilocin—the active metabolite produced after psilocybin is metabolized—produced several noteworthy findings:

* cellular lifespan increased by approximately 29–57%, depending on dose

* telomeres were better preserved

* oxidative stress was reduced

* markers of DNA stability and repair improved

* expression of SIRT1, a protein involved in stress resistance, metabolism, and healthy aging, increased.

The animal study produced equally intriguing observations. Researchers treated 19-month-old female mice—roughly corresponding to humans entering later life—with monthly oral psilocybin.

Compared with untreated animals, the treated mice demonstrated:

* significantly higher survival rates

* healthier fur

* reduced graying

* hair regrowth in some animals

* an overall healthier appearance during aging.

Importantly, treatment began relatively late in life, making the findings particularly interesting from a geroscience perspective.

Researchers found evidence that psilocin influenced several cellular pathways associated with healthy aging in laboratory cells and aged mice. Whether similar effects occur in humans remains unknown.

Why This Study Matters

Until now, most discussions surrounding psilocybin have centered on consciousness, perception, and psychological healing.

This research suggests something broader may be occurring.

Serotonin receptors—including the well-known 5-HT2A receptor—are found not only in the brain but throughout the body, including:

* immune cells

* blood vessels

* the heart

* the gastrointestinal tract

* the liver

* the skin

* connective tissue.

This means that compounds acting on serotonin signaling could potentially influence multiple biological systems, not just brain function.

Exactly how these mechanisms interact remains an active area of investigation.